Cargando…
Patients at the Heart of the Scientific Dialogue: An Industry Perspective
Pharmaceutical companies need to regularly communicate to patients all essential information about their medicines, especially data from the research studies that were conducted to evaluate the medicine’s benefits and risks. To do that, companies will need to make sure patients have access to and aw...
Autores principales: | Habr, Dany, Wolf Gianares, Brittany, Schuler, Kristine W., Chari, Dheepa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9881512/ https://www.ncbi.nlm.nih.gov/pubmed/36705813 http://dx.doi.org/10.1007/s40487-023-00220-z |
Ejemplares similares
-
Correction: Patients at the Heart of the Scientific Dialogue: An Industry Perspective
por: Habr, Dany, et al.
Publicado: (2023) -
Reimagining diversity in multiple myeloma clinical trials
por: Habr, Dany, et al.
Publicado: (2022) -
Age Is Just a Number: Considerations for Older Adults in Cancer Clinical Trials
por: Habr, Dany, et al.
Publicado: (2021) -
How to Account for Asymmetries in Deliberative Dialogues: Comment on "Evaluating Public Participation in a Deliberative Dialogue: A Single Case Study"
por: Jiménez-Pernett, Jaime
Publicado: (2023) -
Improving access to oncology publications for advocates and people with cancer
por: Tabernero, Josep, et al.
Publicado: (2022)